RxDoctor Payments Data

Susan Baez

Psychiatric/Mental Health · Kingston, NYNPI 1497713309

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by AbbVie at 48.2% of the total. 2025 is the largest year on record at $404, 3.1 times the $131 reported in 2021.

$1,406in general payments, 2019–2025

Across 38 payments — averaging $37.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$678
  • Alkermes, Inc.$413
  • Axsome Therapeutics, Inc.$155
  • Otsuka America Pharmaceutical, Inc.$145
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$16

What the payments were for

  • Food & beverage$1,406100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,406 in reported general payments places this provider in the 70th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$39,751
Medicare patients
48
Services billed
535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole12$20,423
TrintellixVortioxetine Hydrobromide14$6,484
Aripiprazole58$5,421
Lurasidone Hcl26$2,725
Asenapine Maleate12$2,179
Bupropion XlBupropion Hcl86$1,952
Venlafaxine Hcl ErVenlafaxine Hcl128$1,613
Perphenazine28$1,387
Methylphenidate Er (La)Methylphenidate Hcl11$1,148
Clonazepam157$1,021
Lamotrigine167$948
Imipramine Hcl40$841
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine24$818
Trazodone Hcl124$752
Methylphenidate Hcl26$662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$145$20,42312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Kingston

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →